First biosimilar for the treatment of cancer gets US FDA green signal


eMediNexus    19 September 2017

Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer has been approved by the US FDA making it the first biosimilar to be approved in the US for the treatment of cancer. Mvasi has been approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.